A subset of ovarian cancer is known to overexpress CCNE1 or CCND1 [8], suggesting that cell-cycle-targeted drugs such as palbociclib, a CDK4/6 inhibitor, may be effective in specific subsets of ovarian cancer [48]. Here, CCNE1 is linked to ovarian carcinoma.